Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0037315 (sleep apnea)
 8,000 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Orlistat (Xenical, Hoffmann-La Roche) is a powerful inhibitor of gastrointestinal lipase and as such, reduces fat absorption. Unlike other weight-reducing drugs it is minimally absorbed and has no effects in the CNS. Orlistat is indicated for patients with a body mass index (BMI) of at least 30 kg/m2 or 28 kg/m2 in the presence of obesity-associated complications, such as hypertension, diabetes mellitus, hyperlipidaemia and obstructive sleep apnoea. In clinical trials, orlistat (120 mg t.i.d.) in combination with life-style modification and a hypocaloric diet (30% of energy from fat) induced significantly more weight loss and improved health complications of obesity (diabetes, hypertension, hyperlipidaemia) compared to patients treated with diet alone. Side effects related to fat malabsorption, occurred in more than 20% of subjects during the first year of treatment and included oily faecal spotting, abdominal pain, flatus with discharge and fatty/oily stool. Side effects from orlistat diminished in the second year of treatment. Plasma concentrations of fat soluble vitamins decreased in orlistat-treated patients but did not usually fall below the normal range. No studies have evaluated the efficacy of orlistat or side effect profile beyond two years.
 ...
PMID:Orlistat in the treatment of obesity. 2694 9

Wind instrument performance is a notable feature in pneumology under aspects of ventilatory physiology and respiratory diseases. It requires an adequate ventilatory function combined with precise control of air flow and the ability to generate sufficient mouth pressures. Depending on the type of wind instrument, the required rates of airway pressure and air flow differ significantly. The cause of respiratory disease in wind instrument players may be related to these increased airway pressures in terms of a barotrauma. Wind instrumentalists may suffer from hemoptysis, laryngoceles, velopharyngeal insufficiency and pneumoparotitis due to their musical performance. Even the development of lung cancer has been assumed to be related to wind instrument playing. Controversy exists about implicating wind instrument use as the cause of pulmonary emphysema or in changes of pulmonary function, which is, however, unlikely under physiological aspects. Furthermore, professional wind instrumentalists may be impaired in their work by the side effects of anti-obstructive medication and respiratory infection. On the other hand, the potential therapeutic effects of wind instrument performance have to be considered. For asthmatic teenagers a significant improvement of pulmonary function and of physical and emotional activities could be related to wind instrument playing. Last but not least, didgeridoo playing was shown to be a promising alternative treatment for obstructive sleep apnoea syndrome.
 ...
PMID:[Pneumological aspects of wind instrument performance--physiological, pathophysiological and therapeutic considerations]. 1807 66

Obesity is associated with increased risk of conditions such as hypertension, dyslipidaemia, diabetes mellitus, and obstructive sleep apnoea. Pharmacotherapy for obesity should be considered in combination with lifestyle changes in obese patients, or overweight patients with other conditions that put them at risk of developing heart disease. Sibutramine and orlistat are the only two anti-obesity medications approved for long-term use. Sibutramine is a serotonergic and adrenergic drug that reduces food intake. Orlistat is a gastrointestinal lipase inhibitor that interferes with fat absorption. However, it commonly causes flatulence and diarrhoea. Rimonabant is the first of a series of endocannabinoid receptor antagonists. It was approved by the Committee for Medicinal Products for Human Use of the European Medicines Agency (EMEA) as an adjunct to diet and exercise in treating obesity in 2006. However, despite the extensive clinical trial data, EMEA announced in 2008 that it has recommended suspension of rimonabant because of its psychiatric side effects. Studies evaluating the long-term safety and efficacy of anti-obesity agents are needed.
 ...
PMID:Pharmacotherapy for obesity. 2000 75